Lars Frelin

Karolinska Institutet

Sweden

Research Interests

Explore related searches

Professors in Sweden Professors in Immunology Immunology professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (14)

Susanna Brighenti

Karolinska Institutet

SWEDEN

View details

Sophia Hober

Professor

KTH Royal Institute of Technology

SWEDEN

View details

Alvaro Haroun-Izquierdo

Karolinska Institutet

SWEDEN

View details

Soo Aleman

Karolinska Institutet

SWEDEN

View details

Laura Marcela Palma Medina

Karolinska Institutet

SWEDEN

View details

Helena Bergsten

Karolinska Institutet

SWEDEN

View details

Isabel María Díaz Lozano

Universidad de Granada

SPAIN

View details

John Tyler Sandberg

Karolinska Institutet

SWEDEN

View details

Malin Flodström Tullberg

Karolinska Institutet

SWEDEN

View details

Anna Pasetto

University of Oslo

NORWAY

View details

Friedemann Weber

GERMANY

View details

Lena Heinrich

University of Twente

NETHERLANDS

View details

Magnus Johansson

Professor

Örebro university

SWEDEN

View details

Gustaf Ahlén

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Lars Frelin

Research Interests

Explore related searches

Contact this professor

Articles (10)

Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease

Phosphatidylinositol 4-Kinase III Alpha Governs Cytoskeletal Organization for Invasiveness of Liver Cancer Cells.

FRI-252 Prophylactic vaccine against hepatitis D virus (HDV) superinfection

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.

A universal SARS‐CoV DNA vaccine inducing highly cross‐reactive neutralizing antibodies and T cells

SAT413 Heterologous prime-boost immunotherapy circumvents tolerance and induces broadly neutralizing antibodies that protects against hepatitis B and D co-infection and hepatitis D super-infection

Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections.

SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation

Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients

The SARS-CoV-2 N Protein Is a Good Component in a Vaccine

Collaborators (14)

Susanna Brighenti

Sophia Hober

Alvaro Haroun-Izquierdo

Soo Aleman

Laura Marcela Palma Medina

Helena Bergsten

Isabel María Díaz Lozano

John Tyler Sandberg

Malin Flodström Tullberg

Anna Pasetto

Friedemann Weber

Lena Heinrich

Magnus Johansson

Gustaf Ahlén

Make your next move.